Dyne Therapeutics to present preclinical DMD data at NMSG meeting
Dyne Therapeutics plans to present preclinical data for multiple DMD candidates at the 27th Annual NMSG Scientific Meeting. The data support four investigational therapies targeting exon skipping 53, 45, 44 or 55, advancing into IND-enabling studies.
Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies -- All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known…